AstraZeneca and Chi-Med’s Savolitinib Shows Encouraging Clinical Activity in 2nd-Line EGFR Mutation-positive Lung Cancer with MET-amplification
New data give insights into disease progression and potential next-generation treatment strategies in patients with EGFR-mutated NSCLC with MET-amplification Data for savolitinib in combination withTagrissoorIressa...
